Anti-depressant - Like Effect of Novel 5-HT$_3$ Receptor Antagonist, (4-benzylpiperazin-1-yl) (3-methoxyquinoxalin-2-yl)methanone (6g) in Acute and Chronic Animal Models of Depression

Radhakrishnan Mahesh, Shvetank Bhatt*, Thangaraj Devadoss, Ankur Kumar Jindal, Baldev Kumar Gautam, Arghya Kusum Dhar, Dilip Kumar Pandey

Department of Pharmacy, FD-III, Birla Institute of Technology & Science, Pilani, Rajasthan-333031, India.

ABSTRACT

A novel 5-HT$_3$ receptor antagonist 6g with a good log P and pA$_H$ value identified from a series of compounds synthesized in our laboratory was subjected to forced swim test (FST) (1 and 2 mg/kg, i.p) and tail suspension test (TST) (0.5–2 mg/kg, i.p.). Compound 6g significantly reduced the duration of immobility in mice without affecting the base line locomotion. Moreover, 6g (1 and 2 mg/kg, i.p.), potentiated the 5-hydroxytryptophan (5-HTP)-induced head twitch responses in mice and reversed the reserpine-induced hypothermia (RIH) in rats. In interaction studies of 6g with various standard drugs/ligands using FST, 6g (1 mg/kg, i.p.) potentiated the anti-depressant effect of venlafaxine, desipramine and fluoxetine and harmine as well as reverse the effect of parthenolide by reducing the duration of immobility in FST. However, 6g (1 and 2 mg/kg, i.p.) has no influence on mCPP induced increase in duration of immobility in FST. Furthermore, 6g (1 mg/kg, i.p.) potentiated the effect of bupropion in TST. Chronic 6g treatment attenuated the behavioral anomalies in olfactory bulbectomy (OBX) rats. In conclusion, these various findings reiterated the anti-depressant-like effects of 6g in behavioral models of depression.

Keywords: Serotonin, quinoxaline, 5-HT$_3$ receptor antagonists, anti-depressant, forced swim test, tail suspension test.

INTRODUCTION

Depression is a serious disorder that, according to the World Health Organization (WHO), is one of the leading causes of disability, worldwide. It is one of the most prevalent and costly psychiatric disorder of the developed world with a lifetime prevalence of between 7.5 and 17%.1,2

The untreated, chronic or recurrent depression may affect the normal physical, mental social life of the depressives and their family members and in worst cases depressives get the suicidal idea and behavior3 and hence, prompt diagnosis and treatment is important to treat this disorder. Several anti-depressant drugs are available to treat this disorder. Regardless of the chemical structures, most of the clinically existing anti-depressant drugs exert their action by elevating the level of monoamine(s) in synapse, either directly or indirectly.3 The older anti-depressant drugs such as monoamine oxidase inhibitors and tricyclic anti-depressants are unfortunately well known for their drug-food/-drug interaction and side-effects rather than their therapeutic efficacy, respectively.3,4 Introduction of 'low side-effect anti-depressants' such as SSRIs for the treatment of depression, enhance the patient's compliance towards pharmacotherapy of depression.6 Moreover these molecules are less effective than the older drug molecules and take 4-6 weeks to produce therapeutic effects.7

Targeting 5-HT$_3$, receptor will be of a notable interest for the development of newer anti-depressants. The beneficial effects of 5-HT$_3$, receptor antagonists (ondansetron, granisetron etc.) are well established for treatment of nausea and vomiting (with fewer or negligible side-effects profile) in several pre-clinical studies.8,9,10,11 The beneficial effects of 5-HT$_3$, receptor antagonists were demonstrated in depression, similarly other researchers have also proved the same12,13,14. Serotonin, a neurotransmitter which has many important implications in the control of numerous behavioral and physiological processes both in peripheral and central nervous system, is known to modulate mood, emotion, sleep, and appetite.15 The 5-HT$_3$, receptors are members of the Cys-loop superfamily of ligand-gated ion channels.16,17 5-HT$_3$, receptor activation either leads to fast excitatory responses or the modulation of neurotransmitter release depending on their neuronal localisation. The involvement of 5-HT$_3$, receptors in depression and anxiety is complemented by studies of 5-HT$_3$, knock out mice which revealed the regulation of 5-HT$_3$, (3A subtype) in depression- and anxiety-related behaviors18. It is reasonable to conclude that 5-HT$_3$, receptors are involved in the modulation of anxiety and depression-related behavior.

*Address for Correspondence:
Mr. Shvetank Bhatt, Department of Pharmacy, FD-III, Birla Institute of Technology & Science, Pilani, Rajasthan-333031, India.
E-mail: shvetankbhatt@gmail.com
and pharmacotherapy targeting 5-HT<sub>1</sub> receptors could be an alternative option for the treatment of depression and anxiety disorders. Evidence for the relevance of 5-HT<sub>1</sub> antagonists in the treatment of depression stems from clinical trials in which patients suffering from complex disorders such as fibromyalgia and bulimia showed improvement of the comorbid depression.<sup>19</sup>,<sup>20</sup>

Using the three-component pharmacophore model<sup>21</sup> a series of 5-HT<sub>1</sub>, receptor antagonists have been designed, synthesized and screened for their 5-HT<sub>1</sub>, antagonist potential (Table 1). The compounds were tested for their ability to inhibit the 5-HT<sub>1</sub> receptor in isolated guinea pig ileum, and the pA<sub>2</sub> values were determined against 2-methyl-5-hydroxytryptamine (HT<sub>3</sub>) receptor in isolated guinea pig ileum, and the pA<sub>2</sub>, values were determined against 2-methyl-5- hydroxytryptamine with ondansetron as a reference drug.<sup>22,23</sup>

Animal models of depression have been utilized vigorously to screen the novel compounds which were originally designed as screening tests to assess the efficacy of anti-depressant drugs.<sup>24</sup> These tests neglect the aspect of face validity but have a strong predictive validity to aid in the identification of efficient anti-depressant molecules.<sup>25</sup> Hence a battery of behavioral tests were adopted for the study which included acute models like Forced Swim Test (FST),<sup>26</sup> Tail Suspension Test (TST)<sup>27,28</sup> mechanistic models like 5-hydroxytryptophan (5-HTP) induced head twitch response in mice and Reserpine Induced Hypothermia.<sup>29</sup> Evaluation of chronic effect of the compound was studied on electrolyte bullectomised rats<sup>30</sup> provide significant information on anti-depressant activity of 6g, which was identified for this study based on pA<sub>2</sub> and log P values.

In the present study, compound 6g (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone which exhibited good log P and pA<sub>2</sub> values (pA<sub>2</sub>, 7.5) greater than the standard 5-HT<sub>1</sub>, receptor antagonist, ondansetron (OND) (pA<sub>2</sub>, 6.9)<sup>31</sup> was selected for the preliminary anti-depressant screening in the standard rodent models of depression as mentioned above.

**MATERIALS AND METHODS**

**Animals**

Albino mice (25±2 g), Wistar rats (250±20 g) and Dunkin Hartley guinea pigs (370±20 g) were obtained from Agricultural University, Hisar, Haryana, India. All procedures were in adherence to Institutional Ethics Committee (IAEC) of Birla Institute of Technology & Science, Pilani, India (Protocol No. IAEC/RES/4/1, dated 13.08.08). The animals were kept for at least one week before the experiments, at optimum temperature (23 ± 2 °C) and humidity-controlled (50-60%) animal rooms under a 12:12 h light/dark cycle (light on 6:00–18:00 h) with free access to food and water ad libitum. Behavioral studies were carried out during the light phase (9.00 a.m.- 2.00 p.m.). The animals were used only once for each experiment.

**Chemistry of (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g)**

The synthetic protocol of the target compound is illustrated in the (Fig 1). The title compound (6g) was synthesized from the starting material, o-phenylenediamine (1) in a sequence of reactions. Initial condensation with diethyl ketomalonate followed by chlorination using phosphorous oxychloride, furnished the chloro ester compound (3) which on saponification followed by nucleophilic displacement with sodium methoxide afforded the key intermediate, 3-methoxyquinoxalin-2-carboxylic acid in quantitative yield (5). The carboxylic acid group of the key intermediate (5) was coupled with benzylpiperazine in the presence of EDC·HCl and HOBT, to afford the desired product 6g in good yield. The compound 6g was converted into hydrochloride salt by using ethanolic hydrochloric acid<sup>31</sup>. The structure of the synthesized compound 6g was confirmed by spectral data; 1H NMR (CDCl<sub>3</sub>, 400 MHz): δ 13.34 (s, 1H, salt proton), 7.87 (d, 1H,}

<table>
<thead>
<tr>
<th>Compd</th>
<th>R</th>
<th>logP&lt;sup&gt;1&lt;/sup&gt;</th>
<th>pA&lt;sub&gt;2&lt;/sub&gt;&lt;sup&gt;2&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>6a</td>
<td>C&lt;sub&gt;2&lt;/sub&gt;H&lt;sub&gt;5&lt;/sub&gt;</td>
<td>3.43</td>
<td>7.2</td>
</tr>
<tr>
<td>6b</td>
<td>o-MeO-C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;4&lt;/sub&gt;-</td>
<td>3.30</td>
<td>6.9</td>
</tr>
<tr>
<td>6c</td>
<td>p-MeO-C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;4&lt;/sub&gt;-</td>
<td>3.30</td>
<td>5.3</td>
</tr>
<tr>
<td>6d</td>
<td>p-Cl-C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;4&lt;/sub&gt;-</td>
<td>3.98</td>
<td>6.7</td>
</tr>
<tr>
<td>6e</td>
<td>m-Cl-C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;4&lt;/sub&gt;-</td>
<td>3.98</td>
<td>7.0</td>
</tr>
<tr>
<td>6f</td>
<td>m-CF&lt;sub&gt;3&lt;/sub&gt;-C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;4&lt;/sub&gt;-</td>
<td>4.35</td>
<td>7.5</td>
</tr>
<tr>
<td>6g</td>
<td>C&lt;sub&gt;6&lt;/sub&gt;H&lt;sub&gt;5&lt;/sub&gt;-CH&lt;sub&gt;2&lt;/sub&gt;-</td>
<td>3.08</td>
<td>7.5</td>
</tr>
<tr>
<td>6h</td>
<td>CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>1.35</td>
<td>6.4</td>
</tr>
<tr>
<td>6i</td>
<td>CH&lt;sub&gt;2&lt;/sub&gt;-CH&lt;sub&gt;3&lt;/sub&gt;-</td>
<td>1.69</td>
<td>5.9</td>
</tr>
<tr>
<td>6j</td>
<td>CH&lt;sub&gt;3&lt;/sub&gt;=CH-CH&lt;sub&gt;3&lt;/sub&gt;-</td>
<td>2.04</td>
<td>4.1</td>
</tr>
<tr>
<td>6k</td>
<td>(Me)&lt;sub&gt;2&lt;/sub&gt;N-CH&lt;sub&gt;2&lt;/sub&gt;-CH&lt;sub&gt;3&lt;/sub&gt;-</td>
<td>1.36</td>
<td>6.1</td>
</tr>
<tr>
<td>6l</td>
<td>(Et)&lt;sub&gt;2&lt;/sub&gt;N-CH&lt;sub&gt;2&lt;/sub&gt;-CH&lt;sub&gt;3&lt;/sub&gt;-</td>
<td>2.04</td>
<td>6.4</td>
</tr>
<tr>
<td>6m</td>
<td>2-((Indol-3-yl)ethyl)-</td>
<td>2.91</td>
<td>5.8</td>
</tr>
<tr>
<td>6n</td>
<td>p-N(Et)&lt;sub&gt;2&lt;/sub&gt;CH&lt;sub&gt;2&lt;/sub&gt;-</td>
<td>3.98</td>
<td>7.0</td>
</tr>
<tr>
<td>6o</td>
<td>3-Pridyl-</td>
<td>1.69</td>
<td>7.2</td>
</tr>
</tbody>
</table>

1 log P values are calculated by using ChemBioDraw Ultra 11 (Cambridge Software).
2 pA<sub>2</sub> values are the means of two separate experiments. SE was less than 10% of the mean.
was purchased from Lancaster chemicals, USA. The drugs for anaesthesia namely, ketamine and xylazine were purchased from Reidel Neon Labs, Indian Immunologicals (Mumbai, India). The drugs were freshly prepared in distilled water and administered per oral (p.o.) or intra-peritoneally (i.p.) (as specified) in a constant volume of 10 ml/kg. For interaction studies, the anti-depressants/ligands and standards were administered i.p., 45 and 30 min, respectively before testing in FST and TST as per the protocol adopted, earlier in our laboratory. The drugs were administered p.o. once a day for 14 days in the chronic treatment schedule.

5-HT receptor antagonistic activity

The compounds were tested for their ability to inhibit the 5-HT receptor in isolated guinea-pig ileum and the pA2 values were determined against 2-methyl-5-hydroxytryptamine. In order to assess the 5-HT receptor antagonistic activity, guinea pigs were sacrificed with ketamine (40 mg/kg, i.p.) and xylazine (5 mg/kg, i.p.). The abdomen was cut open and a length of ileum excised about 2 cm from the ileo-caecal junction, the longitudinal muscle-myenteric plexus (LMMP), 3-4 cm in length was prepared and mounted as cited in the literature. The tissue was equilibrated for 30 min. under a resting tension of 500 mg with constant aeration in a 40 mL organ bath containing Tyrode solution, maintained at 37°C.

Non-cumulative concentrations of 2-methyl-5-HT were added with a 15 min dosing cycle (to prevent desensitization) and left in contact with the tissue until the maximal contraction had developed. To study the antagonist effect of

Drugs and chemicals

Fluoxetine (FLX), paroxetine (PAR), venlafaxine (VLA) and Bupropion (BUP) were obtained as gift samples from Cipla Pharmaceuticals & IPCA Laboratories Private Limited, India respectively. Escitalopram (ESC) & Ondanestron (OND) were obtained as generous gift samples from Glenmark Pharmaceuticals & Natco Pharmaceuticals, India. Desipramine (DMI) & pargyline were purchased from Sigma chemicals, USA. Harmane and 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH DPAT) were purchased from Tocris Bioscience, U.K. meta-Chlorophenylpiprazine (mCPP) was purchased from Lancaster chemicals, USA. The drugs for anaesthesia namely, ketamine and xylazine were purchased from Reidel Neon Labs, Indian Immunologicals (Mumbai, India). The drugs were freshly prepared in distilled water and administered per oral (p.o.) or intra-peritoneally (i.p.) (as specified) in a constant volume of 10 ml/kg. For interaction studies, the anti-depressants/ligands and standards were administered i.p., 45 and 30 min, respectively before testing in FST and TST as per the protocol adopted, earlier in our laboratory. The drugs were administered p.o. once a day for 14 days in the chronic treatment schedule.

5-HT, receptor antagonistic activity

The compounds were tested for their ability to inhibit the 5-HT3 receptor in isolated guinea-pig ileum and the pA2 values were determined against 2-methyl-5-hydroxytryptamine. In order to assess the 5-HT receptor antagonistic activity, guinea pigs were sacrificed with ketamine (40 mg/kg, i.p.) and xylazine (5 mg/kg, i.p.). The abdomen was cut open and a length of ileum excised about 2 cm from the ileo-caecal junction, the longitudinal muscle-myenteric plexus (LMMP), 3-4 cm in length was prepared and mounted as cited in the literature. The tissue was equilibrated for 30 min. under a resting tension of 500 mg with constant aeration in a 40 mL organ bath containing Tyrode solution, maintained at 37°C.

Non-cumulative concentrations of 2-methyl-5-HT were added with a 15 min dosing cycle (to prevent desensitization) and left in contact with the tissue until the maximal contraction had developed. To study the antagonist effect of
the test compounds on the response evoked by 2-methyl-5-HT, the compounds were added to the organ bath and left in contact with the tissue for at least 10 min prior to the addition of 2-methyl-5-HT. The contractions were recorded using a T-305 Force transducer coupled to a Student's physiograph (Bio Devices, Ambala, India). Antagonism was expressed in the form of pA₄ values, which were graphically determined. The pA₄ values of the test compound were compared with the standard antagonist, ondansetron.

**Forced Swim Test (FST)**

The FST was carried out as described elsewhere²⁶ with slight modifications. Mice were dropped individually into a plexiglass cylinder (height: 30 cm, diameter: 22.5 cm) filled with water to a depth of 15 cm and maintained at 23–25 °C. After an initial vigorous activity (2 min), the mice acquired in this test, an immobile posture which was characterized by motionless floating in the water, making only those movements necessary to keep the head above the water. The duration of immobility which reflects the state of depression was recorded during the last 4 min of the 6 min test. The mice were subjected to 15 minute training under similar conditions, 24 h before the test.

**Tail Suspension Test (TST)**

Mice were individually suspended by the tail to a horizontal bar (distance from floor was 50 cm) using scotch tape (distance from tip of tail was approximately 1 cm). Typically, mice exhibited several escape-oriented behavior interspersed with temporally increasing bouts of immobility.²⁷,²⁸ The duration of immobility (in seconds) during the 6-min test session was recorded.

**Spontaneous Locomotor Activity (SLA)**

The SLA was assessed using an actophotometer.³⁴ The animals were individually placed in a square arena (30 cm×30 cm) with walls painted black and are fitted with photocells just above the floor level. The photocells were checked before the beginning of the experiment. After an initial 2 min familiarization period, the digital locomotor scores were recorded for the next 10 min in a dimly lit room. The arena was cleaned with dilute alcohol and dried between trials.

**5-Hydroxytryptophan (5-HTP) induced head twitch response**

The method mentioned elsewhere³⁵ was adopted with slight modifications. The vehicle/drug treated mice were injected with pargyline (75 mg/kg i.p) and 5-HTP (5 mg/kg), 30 and 15 min prior to drug administration respectively and gently placed in separate, clear plexi-glass cages (12×12×10 cm). The total number of head twitches (characterized by abrupt lateral movements) episodes were recorded for the next 15 min.

**Interaction studies in FST and TST**

The animals were treated either with vehicle or with one of the following test compounds namely, FLX (10 and 20 mg/kg, i.p.), a serotonin re-uptake inhibitor, DMI (10 and 20 mg/kg, i.p.), a nor-epinephrine reuptake inhibitor, VLA (4 and 8 mg/kg, i.p.), a serotonin nor-epinephrine reuptake, harmamine (5mg/kg, i.p.), a monoamine oxidase inhibitor, 8-OH DPAT (1 mg/kg i.p.), 5-HT₄, and 5-HT₃, partial agonist, parthenolide (1 mg/kg i.p.), a serotonin release inhibitor, mCPP (2 mg/kg, i.p.), a 5-HT₁₄₂₅ agonist, a tryptophan hydroxylase inhibitor. Interaction of bupropion (10 and 20 mg/kg, i.p), a nor-epinephrine and dopamine re-uptake inhibitor was carried out in TST since it is more sensitive than that of FST.³⁶,³⁷ All the standard drug doses were adopted from the previous work and standard responses recorded.³⁶,³⁷

**Reserpine induced Hypothermia (RIH) in rats**

Rats were gently hand-restrained and the glycerol lubricated digital thermometer probe was inserted into the rectum. The rectal temperature of the rats treated with reserpine (1 mg/kg, i.p.) was recorded at 30, 60, 90 and 120 min after the drug administration. The difference in the rectal temperature between the baseline and 60⁰ min values were tabulated. On the day preceding of experimentation, the rectal temperature of the rats were assessed in a similar manner in order to habituate the animals to the experimental procedures.³⁸

**Olfactory bulbectomy**

**Surgery**

Bilateral olfactory bulbectomy (OBX) was carried out as described.²⁹,³⁰ In brief, the rat was anaesthetized with a combination of ketamine (75 mg/kg, i.p.) and xylazine (5 mg/kg, i.p.). The head was fixed to a stereotaxic frame (Inco, India) and the skull exposed by a midline incision. Burr holes (2 mm in diameter) were drilled 8 mm anterior to bregma and 2 mm on either side of the midline at a point corresponding to the posterior margin of the orbit of the eye. The dura was punctured and the olfactory bulbs were removed by suction. Haemostatic sponge was used to prevent excessive bleeding and to fill the dead space. The scalp was then sutured and the wound was dabbed with antiseptic solution. Sham surgery was carried out in the same way (including the piercing of the dura matter) except that olfactory bulbs were left intact. Sulprim (each ml containing 200 and 40 mg of sulphadiazine and trimethoprim respectively), was administered (0.2 ml/300 g, i.m.) once a day for the first 3 days for both OBX and sham operated rats. The animals were individually housed for the first 3 days following surgery and thereafter in groups of two (one sham and one OBX rat) until the end of the study. The olfactory bulbectomised and sham rats were allowed 14 day rehabilitation period during which they were
handled by the same experimenter to prevent aggression which would have developed, otherwise. The surgery, rehabilitation, treatment and behavioral screening of OBX/sham rats were carried out based on the customized schedule previously reported.29

Open field test (OFT) behavior

OBX and sham control rats were subjected to the OFT on 29th day after surgery. The open field exploration was conducted as described elsewhere29 with substantial modifications. The apparatus consisted of a circular (90-cm diameter) arena with 75-cm high aluminium walled walls and floor equally divided into 10 cm squares. A 60 W light bulb was positioned 90 cm above the base of the arena, which was the only source of illumination in the testing room. Each animal was individually placed in the center of the OFT apparatus and the following parameters such as ambulation scores (number of squares crossed), number of rearing episodes (when the rat stands upright on its hind paws) and number of fecal pellets were noted for 5 min by a trained observer, unaware of the specific treatments. After each test, the apparatus was sprayed with dilute alcohol and wiped thoroughly.

Statistical analysis

Data were expressed as the mean ± SEM. The single treatment studies were analyzed using a one-way analysis of variance followed by a post-hoc Dunnett test. The interaction studies were analyzed using a two-way analysis of variance followed by a post-hoc Tukey test. The level of statistical significance was fixed at p < 0.05.

RESULTS

Based on the pA4 and log P values, compound 6g was taken for extensive behavioral pharmacological testing from amongst the series of compounds.

In FST, the acute treatment with 6g (1 and 2 mg/kg, i.p.) significantly decreased the duration of immobility as compared to vehicle treatment (Fig. 3). The anti-depressant effect of 6g was dose dependent, i.e. the lower dose (0.5 mg/kg, i.p.) failed to reach the level of significance. Likewise, a significant decrease in duration of immobility was evident at 6g (0.5-2 mg/kg) in the TST (Fig.4). The standard anti-depressants, escitalopram (10 mg/kg) and bupropion (20 mg/kg) also significantly reduced the immobility duration in FST and TST respectively, as compared to the control group. Furthermore, ondansetron (1 mg/kg), significantly reduced the immobility duration in FST and TST as compared to the control group. None of the tested doses influenced the locomotion of mice in actophotmeter. Depletion of brain serotonin induced by reserpine affects the central nervous system as demonstrated by reserpine induced hypothermia. Administration of reserpine (1 mg/kg i.p) elicited a

pronounced decrease in core body temperature of rats. This effect was significantly (p <0.05) reversed by 6g, ondansetron (1 mg/kg) and escitalopram (10 mg/kg) treatments (Fig. 5).

5-HTP-induced head twitches were performed to confirm the involvement of serotonergic pathway. The combination of 5-HTP (5 mg/kg, i.p.) and pargyline (75 mg/kg, i.p.) induced the characteristic head twitch response. 6g (1 and 2 mg/kg, i.p.), ondansetron (1 mg/kg, i.p.) and fluoxetine (20 mg/kg, i.p.) significantly potentiated the 5-HTP/pargyline induced head twitches, respectively (Fig. 6).

The peak dose of 6g (1 and 2 mg/kg, i.p.) that induced a significant (p< 0.05) decrease in the duration of immobility was selected for the interaction studies. The reference compounds were tested individually to determine their effects in FST and TST. 6g (1 and 2 mg/kg, i.p.) significantly (P<0.05) affect the duration of immobility throughout the interaction study as compared to control.
For a conclusive evaluation of anti-depressant potential of 5-HT receptor antagonists, interaction studies with SSRIs were carried out. 6g pre-treatment (1mg /kg, i.p.) was found to enhance anti-depressant-like effects of FLX (10 and 20 mg/kg, i.p.), VLA (4 & 8 mg/kg, i.p.) and DMI (10 and 20 mg/kg, i.p.) as shown in Fig. 7-9 respectively. Moreover, 8-OH-DPAT (1 mg/kg, i.p.), showed anti-depressant effects in the FST and 6g (1 mg/kg, i.p.) potentiated the anti-depressant activity of 8-OH-DPAT as shown in (Fig. 10). Pre-treatment with 6g (1 and 2 mg/kg, i.p.) enhanced the anti-depressant-like effects of harmine (5 mg/kg, i.p.) (Fig. 11). Although 6g (1 and 2 mg/kg, i.p.) failed to reverse the depression-like effects of mCPP (2 mg/kg, i.p.) as shown (Fig. 12). 6g significantly reversed the depressant-like effect of parthenolide (1 mg/kg, i.p.) as shown (Fig. 13). Further 6g (1 mg/kg) significantly enhanced the anti-depressant activity of BUP (10 and 20 mg/kg) in mice TST (Fig. 14).
Fig. 14: Effect of 6g (1 mg/kg) on anti-depressant activity of bupropion (BUP) in mice TST. The columns represent mean duration of immobility in seconds (s) and error bars indicate S.E.M. n = 6 per group. *P < 0.05 vs. vehicle treated Group, P < 0.05 compared with bupropion (10 and 20 mg/kg) treated group and P < 0.05 compared with alone 6g treated group.

The effects of 6g on the behavior of OBX/sham rats were analyzed in different circumstances as shown in (Fig. 15A, 15 B, 15 C). Chronic (14 days, p.o) treatment with 6g (1 and 2 mg/kg) significantly (p< 0.05) reduced the number of ambulation, rearing and fecal pellets in OBX rats as compared to the vehicle treated OBX rats. Moreover, OND (1 mg/kg, i.p.) and PAR (10 mg/kg) also significantly reduced the number of ambulation, rearing and fecal pellets as compared to control group.

DISCUSSION

Animal studies led to the consensus that 5-HT antagonists have anti-depressant effects by blocking limbic hyperactivity response. Since 5-HT, receptors are expressed in brain areas implicated in anxiety and mood more over 5-HT, antagonists...
are able to pass the blood–brain barrier\textsuperscript{40,41} they represent excellent therapeutic candidates. In the present study, 6g, a selective 5HT\textsubscript{3} receptor antagonist revealed the anti-depressant like effect. The psychomotor stimulation/sedation may increase/decrease the locomotor status (global motor activity) of mice in behavioral assays (FST and TST), when interpreting the depressive or anti-depressant-like effect of a new chemical entity (NCE). To rule out non-specific motor effects of 6g in the present study that could influence the activity in the FST and TST, the locomotor activity of 6g in mice was evaluated. None of the tested doses of 6g influenced the locomotion of mice in actophotometer, which suggesting that the anti-depressant-like activity of 6g was not associated with any global motor impairment.

The anti-depressant-like activity of a compound is determined by a decrease in the duration of immobility during the FST and TST. Both of these models of depression are widely used to screen NCE is for their anti-depressant potential.\textsuperscript{26,27} These tests are quite sensitive and relatively specific to all classes of anti-depressants. In the present study, 6g significantly decreased the duration of immobility in mice during the FST and TST. The decreased duration of immobility in mice FST and TST reflects the anti-depressant-like activity of a compound.

In mechanistic models, reserpine being a monoamine depleting agent, which acts by blocking the monoamine transport in synaptic vesicle. The depletion of brain biogenic amines affect the central nervous system characterized by hypothermia.\textsuperscript{38} The decrease in body temperature induced by reserpine was reported to be antagonized by anti-depressants.\textsuperscript{38} 6g and escitalopram significantly prevented the hypothermic effect of reserpine exhibiting anti-depressant effects in this sensitive model.

5-HTP being the immediate precursor of 5-HT, significantly increases the serotonergic transmission inducing a characteristic head twitch response in mice. 6g increased the head twitches in presence of pargyline, a MAO inhibitor. In this regard, the anti-depressant-like effect of 6g appears to be modulated by an increase in monoamines; particularly 5-HT concentrations in the synapse.\textsuperscript{35}

As these mechanistic models gives us certain clue regarding the mechanism of 6g which could be mainly through modulation of serotonin in synaptic cleft, further interaction studies was performed.

Interaction studies with ligands/conventional anti-depressants in FST and TST were carried out not only to predict the probable mechanism (possible receptor targets) of anti-depressant-like effects of 6g, but also to pharmacologically validate the 6g induced anti-depressant

---

**Fig. 15 A:** Effects of paroxetine (10 mg/kg, po) and 6g (1 and 2 mg/kg, po) open field behavior (ambulation) in OBX/sham rats.

**Fig. 15 B:** Effects of paroxetine (10 mg/kg, po) and 6g (1 and 2 mg/kg, po) on the open field behavior (rearing) in OBX/sham rats.

**Fig. 15 C:** Effects of paroxetine (10 mg/kg, po) and 6g (1 and 2 mg/kg, po) on the open field behavior (fecal pellet) in OBX/sham rats.
like behavior in the above mentioned predictive tests. For a conclusive evaluation of anti-depressant potential of 5-HT, receptor antagonists, interaction studies with standard ligands/conventional anti-depressants were carried out.\textsuperscript{42} \textsuperscript{6g} (1 mg/kg, i.p.), significantly enhanced the anti-depressant-like action of FLX (10 and 20 mg/kg, i.p.). VLA, a SNRI in a lower dose range (2–8 mg/kg), mainly influences the serotoninergic system, whereas at higher doses the involvement of the nor-epinephrine (NE) system predominate.\textsuperscript{43,44} \textsuperscript{6g} (1 mg/kg, i.p.), significantly enhanced the anti-depressant-like action of VLA (4 and 8 mg/kg, i.p.). DMI a tricyclic anti-depressant inhibits the reuptake of nor-epinephrine and to a lesser extent that of serotonin.\textsuperscript{45} \textsuperscript{6g} (1 mg/kg, i.p.), potentiated the effect of desipramine (10 and 20 mg/kg, i.p.) by decreasing the duration of immobility, indicating the influence of nor-adrenergic system by \textsuperscript{6g}.

Potentiation of anti-depressant effects of 8-OH-DPAT (1 mg/kg, i.p.), a 5-HT\textsubscript{1A} and 5-HT, partial agonist\textsuperscript{46} in FST, points to tricyclic anti-depressant (TCA)-like activity of compound \textsuperscript{6g} (1 mg/kg, i.p.).\textsuperscript{47} Harmane, a \(\beta\)-caroline alkaloid, increases the monoamine levels by inhibiting the enzyme monoaamine oxidase-A and B.\textsuperscript{48} \textsuperscript{6g} (1 and 2 mg/kg, i.p.) decreases the duration of immobility and influenced the effect of harmane (5 mg/kg, i.p.) in FST. Previous studies in our laboratory have shown that acute administration of mCPP (2 mg/kg, i.p.) induces a depressogenic-like effects in rodents, and this effect is primarily mediated by stimulation of 5-HT\textsubscript{2A/C} receptors.\textsuperscript{49} \textsuperscript{6g} (1 and 2 mg/kg, i.p.) incapable of reverse the depressogenic effect of mCPP (2 mg/kg, i.p.) which further indicates that \textsuperscript{6g} has no effect on 5-HT\textsubscript{2A/C} receptors. Parthenolide, a serotonin release inhibitor\textsuperscript{50} that produces depressant-like effects\textsuperscript{51} was tested with \textsuperscript{6g} to explore the serotoninergic influence of \textsuperscript{6g}. A depressant-like effect induced by parthenolide was considered as a model to identify anti-depressants acting through serotoninergic mechanisms.\textsuperscript{52} \textsuperscript{6g} (1 and 2 mg/kg, i.p.) reverse the depressogenic effect of parthenolide (1 mg/kg, i.p.) possibly through serotonin release. \textsuperscript{6g} (1 mg/kg, i.p.) potentiates the effect of BUP (10 and 20 mg/kg, i.p.) possibly by interacting with the dopaminergic system, following the dopamine hypothesis of depression.\textsuperscript{53} Though the exact mechanism is not clear, it could be due to the release of dopamine through inhibition of 5-HT\textsubscript{3} receptors.\textsuperscript{54}

Olfactory bulbectomy has been proposed to be an agitated hypo-serotonergic model of depression\textsuperscript{1} and is used to explore the anti-depressant potential of novel agents.\textsuperscript{55} OBX rats exhibited a specific, abnormal behavioral pattern in the open field test characterized by increased ambulation, rearing and fecal pellets, and this abnormal behavior is reversed by anti-depressants\textsuperscript{56}. The Increased locomotor/exploratory behaviour of OBX rat in open field test may be due to exposure to a novel environment.\textsuperscript{57} Moreover, other possible reason for hyperactivity of OBX rats in OFT may be due to decrease in activity in competing behaviour or delay/ failure to habituate to novel environment.\textsuperscript{58}

The present neuro-behavioral investigation showed anti-depressant-like effects of \textsuperscript{6g}, a novel 5-HT, antagonist, in animal models of depression. Though the precise mechanism by which \textsuperscript{6g} produced anti-depressant-like effect is not clear. However, on the basis of results obtained in various mechanistic and interaction studies like potentiation of head twitch responses and reversal of reserpine induced hypothermia suggests that, \textsuperscript{6g} exhibited anti-depressant-like effect by increasing the concentration of neurotransmitter in the synapse. Increase in serotonin level through blockade of 5-HT\textsubscript{3} receptor could possibly explain the overall anti-depressant-like effect of \textsuperscript{6g}. Reversal of parthenolide induced depression-like behavior indicated the anti-depressant-like action of \textsuperscript{6g} via serotonergic modulation.

**CONCLUSION**

In this study, we have designed and synthesized a series of structurally novel 3-methoxyquinoxalin-2-carboxamides as 5-HT, receptor antagonists using ligand-based approach from the starting material o-phenylenediamine. All the synthesized compounds displayed antagonism towards, 5-HT, receptor, compounds \textsuperscript{6f} and \textsuperscript{6g} were the most active compounds among the synthesized molecules. Compound \textsuperscript{6g}, showed anti-depressant-like effects in rodents' models of depression, without affecting the locomotion of rodents. The interaction studies with several standard ligands/anti-depressants, indicates compound \textsuperscript{6g} elicit the anti-depressant-like effect by enhancing the level of monoamine in synapse probably through 5-HT, receptor antagonism. These results correlated the beneficial effects of 5-HT, receptor antagonist in depression. \textsuperscript{6g} potentiate the effects of anti-depressants, which indicate the combination of anti-depressant with 5-HT, receptor antagonist can potentially accelerate the onset of anti-depressant action. Further studies on \textsuperscript{6g} are required to furnish a clinically useful anti-depressant agent, which would be futuristic extension of the present study.

**ACKNOWLEDGMENTS**

We thank the University Grants Commission (UGC), India, Birla Institute of Technology & Science (BITS), Pilani, India and SAIF, Panjab University, Chandigarh, India for providing financial support, laboratory and analytical facilities, respectively. We also express our gratitude to IPCA, Cipla, Natco and Glenmark Laboratories, India for providing drug sample in short notice.
REFERENCES


25. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997; 8: 523−32.


